We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+6.94%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$54.2B
AUM Growth
+$30.1B
Cap. Flow
+$28.6B
Cap. Flow %
52.81%
Top 10 Hldgs %
15.56%
Holding
4,600
New
1,635
Increased
1,281
Reduced
635
Closed
782

Sector Composition

Rank Sector Weight
1 Technology 17.77%
2 Healthcare 17.47%
3 Financials 15.58%
4 Consumer Discretionary 12.3%
5 Communication Services 8.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LGHL
3301
Lion Group Holding
LGHL
$987K
0
EVER icon
3302
EverQuote
EVER
$958M
$113K ﹤0.01%
7,244
-260,626
-97% -$3.98M
BKCC
3303
DELISTED
BlackRock Capital Investment Corporation
BKCC
$112K ﹤0.01%
+27,894
New +$117K
UPH.WS
3304
CALL
DELISTED
UpHealth, Inc. Warrants exercisable for one share of Common Stock at an exercise price of $115.00 per share
UPH.WS
$112K ﹤0.01%
+50,000
New +$18.4K
THRN
3305
DELISTED
Thorne Healthtech, Inc. Common Stock
THRN
$112K ﹤0.01%
+17,952
New +$140K
OIIM
3306
DELISTED
02Micro International
OIIM
$112K ﹤0.01%
+24,547
New +$139K
BRT
3307
BRT Apartments
BRT
$283M
$109K ﹤0.01%
+4,553
New +$91.1K
THR
3308
DELISTED
Thermon Group Holdings
THR
$109K ﹤0.01%
+6,482
New +$113K
VISL
3309
DELISTED
Vislink Technologies, Inc. Common Stock
VISL
$108K ﹤0.01%
+4,586
New +$143K
MOR
3310
DELISTED
MorphoSys AG American Depositary Shares
MOR
$107K ﹤0.01%
11,298
-21,195
-65% -$225K
VIRX
3311
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$106K ﹤0.01%
+29,001
New +$155K
EWZ icon
3312
iShares MSCI Brazil ETF
EWZ
$9.16B
$104K ﹤0.01%
+3,691
New +$111K
KLTR icon
3313
Kaltura
KLTR
$217M
$104K ﹤0.01%
30,970
-94,511
-75% -$627K
CAC icon
3314
Camden National
CAC
$972M
$102K ﹤0.01%
+2,112
New +$101K
DOC
3315
DELISTED
PHYSICIANS REALTY TRUST
DOC
$102K ﹤0.01%
+5,434
New +$100K
KEP icon
3316
Korea Electric Power
KEP
$15.1B
$101K ﹤0.01%
+11,032
New +$104K
TLS icon
3317
Telos
TLS
$343M
$101K ﹤0.01%
+6,565
New +$140K
ACTG icon
3318
Acacia Research
ACTG
$451M
$100K ﹤0.01%
19,327
-162,437
-89% -$877K
NOA
3319
North American Construction
NOA
$368M
$100K ﹤0.01%
+6,594
New +$101K
ILLM
3320
DELISTED
illumin Holdings Inc. Common Shares
ILLM
$100K ﹤0.01%
+26,555
New +$125K
RAAS
3321
DELISTED
Cloopen Group Holding Limited American Depositary Shares (each representing six (6) Class A Ordinary Shares)
RAAS
$100K ﹤0.01%
11,444
-133,274
-92% -$1.51M
ANZ
3322
DELISTED
AUSTRALIA & NW ZEAL ADS(RP5 SH
ANZ
$100K ﹤0.01%
+4,985
New +$100K
IIN
3323
DELISTED
IntriCon Corporation
IIN
$99K ﹤0.01%
+6,192
New +$106K
PG icon
3324
PUT
Procter & Gamble
PG
$352B
$98K ﹤0.01%
600
-73,200
-99% -$10.9M
ZDGE icon
3325
Zedge
ZDGE
$39.3M
$98K ﹤0.01%
+11,497
New +$126K

Similar funds

Marshall Wace's Q4 2021 Portfolio in Review

As of Q4 2021, Marshall Wace held 4,600 positions worth $54.2B, up 125% from $24.1B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Marshall Wace deployed $28.6B of net new capital in Q4 2021, opening 1,635 new positions and adding to 1,281 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 1,140,732 shares worth $542M.

By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Accenture, an estimated $192M trimmed.

  • Marshall Wace's largest Q4 2021 buy was State Street SPDR S&P 500 ETF Trust: 1,140,732 shares worth $542M.
  • Marshall Wace added most to Microsoft in Q4 2021, an estimated $1.08B increase.
  • Marshall Wace's biggest Q4 2021 reduction was Accenture, cutting an estimated $192M.
  • Marshall Wace fully exited Sabre in Q4 2021, selling an estimated $44.1M.
  • Marshall Wace's ten largest holdings make up 16% of its $54.2B portfolio in Q4 2021.
  • Marshall Wace opened 1,635 new positions and closed 782 in Q4 2021.
  • Marshall Wace's portfolio value rose 125% quarter-over-quarter to $54.2B.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.